Year | Drug | Mechanism of action | Participants | Main reasons for failure | Remarks |
---|---|---|---|---|---|
2016 | Solanezumab | Monoclonal antibody | Mild AD | Lack of efficacy | Â |
 | Solanezumab | Monoclonal antibody | Prodromal AD | Strategic |  |
 | Verubecestat | BACE inhibitor | Mild to moderate AD | Lack of efficacy |  |
2018 | Verubecestat | BACE inhibitor | Prodromal AD | Lack of efficacy | Worsens cognition |
 | Atabecestat | BACE inhibitor | Preclinical AD | Toxicity | Worsens cognition |
 | Lanabecestat | BACE inhibitor | Early AD | Lack of efficacy | Worsens cognition |
 | Lanabecestat | BACE inhibitor | Mild AD | Lack of efficacy | Worsens cognition |
2019 | Aducanumab | Monoclonal antibody | Early AD | Lack of efficacy | Â |
 | CNP520 | BACE inhibitor | Preclinical AD | Lack of efficacy | Worsens cognition |